You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

BTK inhibitors

Showing 1 - 25 of 4,305
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

CLL/SLL Trial (lisaftoclax +BTK inhibitor, BTK inhibitor)

Not yet recruiting
  • CLL/SLL
  • lisaftoclax +BTK inhibitor
  • BTK inhibitor
  • (no location specified)
Oct 26, 2023

BTK Inhibitors-related AF Treated by Catheter Ablation

Not yet recruiting
  • BTKi-induced Atrial Fibrillation
  • +2 more
  • Atrial fibrillation catheter ablation in a population of BTKi-induced atrial fibrillation
  • Caen, Normandy, France
    Caen University Hospital
Nov 10, 2023

Atrial Fibrillation Trial in Caen (Insertable subcutaneous cardiac monitor (BIOMONITOR IIIm®, Biotronik®))

Not yet recruiting
  • Atrial Fibrillation
  • Insertable subcutaneous cardiac monitor (BIOMONITOR IIIm®, Biotronik®)
  • Caen, Normandie, France
    Caen University Hospital, Department of Pharmacology
Sep 6, 2023

Newly Diagnosed Mantle Cell Lymphoma Trial in Zhengzhou (Rituximab)

Recruiting
  • Newly Diagnosed Mantle Cell Lymphoma
  • Zhengzhou, Henan, China
    Department of Oncology, The First Affiliated Hospital of Zhengzh
Aug 17, 2022

Cardiac Arrhythmias in Subjects Treated With BTK Inhibitors

Recruiting
  • Chronic Lymphocytic Leukemia (CLL)
  • +5 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Feb 16, 2023

    Chronic Lymphocytic Leukemia (CLL), Waldenstrom Macroglobulinemia (WM) Trial in Rochester (Shingrix vaccine)

    Completed
    • Chronic Lymphocytic Leukemia (CLL)
    • Waldenstrom Macroglobulinemia (WM)
    • Shingrix vaccine
    • Rochester, New York
      University of Rochester
    Jan 9, 2023

    Atrial Fibrillation, Supraventricular Arrhythmia, Ventricular Arrhythmias and Cardiac Arrest Trial in New Hyde Park (Medtronic

    Recruiting
    • Atrial Fibrillation
    • +4 more
    • Medtronic LINQ-2 Insertable Cardiac Monitor (ILR)
    • New Hyde Park, New York
      Northwell (Northshore University/Long Island Jewish Hospitals)
    Dec 1, 2022

    Primary CNS Lymphoma Trial in Zhengzhou (the dose-escalation phase)

    Recruiting
    • Primary Central Nervous System Lymphoma
    • the dose-escalation phase
    • Zhengzhou, Henan, China
      Oncology Department of The First Affiliated Hospital of Zhengzho
    May 30, 2022

    Non-GCB/ABC DLBCL Trial in Suzhou (Zanubrutinib, Rituximab, Cyclophosphamide)

    Recruiting
    • Non-GCB/ABC Diffuse Large B-Cell Lymphoma
    • Suzhou, Jiangsu, China
      The First Affiliated Hospital of Soochow University
    Apr 12, 2021

    Recurrent Refractory Mantle Cell Lymphoma

    Recruiting
    • Mantle Cell Lymphoma
      • Beijing, Beijing, China
        Peking University Third Hospital
      Aug 1, 2022

      r/r B-cell Lymphoma Intolerant to Other Bruton Tyrosine Kinase

      Not yet recruiting
      • B-cell Lymphoma
      • Beijing, Beijing, China
        Deparment of Hematology, Peking University People's Hospital
      Aug 9, 2022

      Warm Autoimmune Hemolytic Anemia Trial in Beijing (Zanubrutinib)

      Not yet recruiting
      • Warm Autoimmune Hemolytic Anemia
      • Beijing, Beijing, China
        Peking Union Medical College Hospital
      Jun 20, 2023

      Molecular Classification of Relapsed/Refractory Diffuse Large

      Completed
      • Lymphoma, Large B-Cell, Diffuse
      • Gene Expression Profiling
      • Gene expression profile
      • Shanghai, Shanghai, China
        Yian Zhang
      Mar 31, 2022

      B-cell Non Hodgkin Lymphoma Trial in Xuzhou (regimen with BTK inhibitor +Anti-CD19 CAR T cells)

      Recruiting
      • B-cell Non Hodgkin Lymphoma
      • regimen with BTK inhibitor +Anti-CD19 CAR T cells
      • Xuzhou, Jiangsu, China
        The Affiliated Hospital of Xuzhou Medical University
      Feb 23, 2023

      Mantle Cell Lymphoma (MCL) Trial in China (LP-168)

      Not yet recruiting
      • Mantle Cell Lymphoma (MCL)
      • Hefei, Anhui, China
      • +29 more
      Feb 7, 2023

      Chronic Lymphocytic Leukemia Trial (Evaluation of response to treatment with response-tailored Ibrutinib in patients with

      Not yet recruiting
      • Chronic Lymphocytic Leukemia
      • Evaluation of response to treatment with response-tailored Ibrutinib in patients with chronic lymphocytic leukemia
      • (no location specified)
      Dec 27, 2022

      Neuromyelitis Optica Spectrum Disorder Trial in Beijing (Orelabrutinib)

      Not yet recruiting
      • Neuromyelitis Optica Spectrum Disorder
      • Beijing, Beijing, China
        Peking Union Medical College Hospital, Chinese Academy of Medica
      Mar 16, 2022

      Monoclonal Gammopathy of Uncertain Significance Trial in Utrecht (Zanubrutinib Oral Product)

      Not yet recruiting
      • Monoclonal Gammopathy of Uncertain Significance
      • Zanubrutinib Oral Product
      • Utrecht, Netherlands
        University Medical Center Utrecht
      Jul 6, 2023

      Tafasitamab in Combination With Lenalidomide in Patients withR/R

      Not yet recruiting
      • Diffuse Large B-cell Lymphoma
      • Tafasitamab Injection
      • Shanghai, China
        Ruijin Hospital, Shanghai Jiao Tong University School of Medicin
      May 31, 2023

      Relapsed/Refractory B-Cell Malignancies Trial in Australia, China (HSK29116)

      Recruiting
      • Relapsed/Refractory B-Cell Malignancies
      • Perth, Australia
      • +7 more
      Aug 1, 2022

      CLL/SLL, NHL Trial in China (BN102)

      Not yet recruiting
      • CLL/SLL
      • NHL
      • Guangzhou, China
      • +5 more
      May 4, 2022

      Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma Trial (Pirtobrutinib, LV20.19 CAR T cells)

      Not yet recruiting
      • Non Hodgkin Lymphoma
      • +5 more
      • (no location specified)
      Aug 4, 2023

      Waldenström's Macroglobulinemia Trial in Worldwide (BGB-3111, Ibrutinib)

      Completed
      • Waldenström's Macroglobulinemia
      • Phoenix, Arizona
      • +79 more
      Jul 6, 2022

      Hepatitis, Safety and Tolerability Trial run by the NHLBI (HEPLISAV-B)

      Completed
      Has Results
      • Hepatitis
      • Safety and Tolerability
      • HEPLISAV-B
      • Bethesda, Maryland
        National Institutes of Health Clinical Center
      Jan 13, 2022

      CNS Lymphoma, Secondary CNS Lymphoma Trial run by the National Cancer Institute (NCI) (TEDD-R, TEDDI-R, Ibrutinib)

      Recruiting
      • Central Nervous System Lymphoma
      • Secondary Central Nervous System Lymphoma
      • Bethesda, Maryland
        National Institutes of Health Clinical Center
      Jan 23, 2023